Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial
Rong Tang, Hui Zheng, Busen Wang, Jin-Bo Gou, Xiling Guo, Xiaoqin Chen, Yin Chen, Shipo Wu, Jin Zhong, Hongxing Pan, Jiahong Zhu, Xiaoyu Xu, Fengjuan Shi, Zhuo-Pei Li, Jingxian Liu, Xiaoyin Zhang, Lunbiao Cui, Zhizhou Song, Lihua Hou, Fengcai Zhu, Jingxin Li, Hai-Tao Huang, Xiaolong Li, Xue Wang, Peng Wan, Tao Zhu
Topics & Concepts
ImmunogenicityBooster doseMedicineBooster (rocketry)Coronavirus disease 2019 (COVID-19)VaccinationCohortSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyImmunologyAntibodyInternal medicineImmunizationAstronomyPhysicsInfectious disease (medical specialty)DiseaseSARS-CoV-2 and COVID-19 ResearchIntramuscular injections and effectsAnimal Virus Infections Studies